Drug Trial Radar · NCT06360133
Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease
Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
700
Planned (sponsor's estimate)
Start
Apr 1, 2024
Primary completion
Apr 30, 2027
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- VivaVision Biotech, IncIndustry
- Sponsor type
- Industry
- First posted
- Apr 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 30 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, randomized, double-Masked, vehicle-controlled, multi-center study designed to evaluate the safety and efficacy of 5% VVN001 Ophthalmic Solution versus vehicle in Chinese subjects with dry eye disease.
Conditions
- Dry Eye
Interventions
VVN001 Ophthalmic Solution, 5%Drug
VVN001 Ophthalmic Solution, 5%
VVN001 Ophthalmic Solution, VehicleDrug
VVN001 Ophthalmic Solution, Vehicle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Corneal Fluorescein StainingTime frame: Day 84
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Eye & Ent Hospital of Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.